- call +1-201-465-4211
- email sales@mrinsights.biz
PARP inhibitors are a group of pharmacological inhibitors of the enzyme poly ADP ribose polymerase (PARP).
They are developed for multiple indications; the most important is the treatment of cancer. Several forms of cancer are more dependent on PARP than regular cells, making PARP an attractive target for cancer therapy. PARP inhibitors appear to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer, as evidenced mainly by olaparib added to conventional treatment.
Scope of the Report:
PARP (Poly ADP-Ribose Polymerase) Inhibitor first approval in United States in 2014. And in the last several years, global market (value) of PARP (Poly ADP-Ribose Polymerase) Inhibitor developed rapidly, with an average growth rate of 133.8% during 2015 to 2018.
The classification of PARP (Poly ADP-Ribose Polymerase) Inhibitor includes Lynparza, Zejula, Rubraca, Talzenna and other. Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.
The worldwide market for PARP (Poly ADP-Ribose Polymerase) Inhibitor is expected to grow at a CAGR of roughly 31.4% over the next five years, will reach 4855 million US$ in 2024, from 1239.9 million US$ in 2019.
This report focuses on the PARP (Poly ADP-Ribose Polymerase) Inhibitor in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
AstraZeneca
Tesaro
Merck & Co
Clovis Oncology
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Lynparza
Zejula
Rubraca
Talzenna
Other
Market Segment by Applications, can be divided into
Ovarian Cancer
Breast Cancer
Other
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of PARP (Poly ADP-Ribose Polymerase) Inhibitor, with price, sales, revenue and global market share of PARP (Poly ADP-Ribose Polymerase) Inhibitor in 2017 and 2018.
Chapter 3, the PARP (Poly ADP-Ribose Polymerase) Inhibitor competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the PARP (Poly ADP-Ribose Polymerase) Inhibitor breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, PARP (Poly ADP-Ribose Polymerase) Inhibitor market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe PARP (Poly ADP-Ribose Polymerase) Inhibitor sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 PARP (Poly ADP-Ribose Polymerase) Inhibitor Introduction
1.2 Market Analysis by Type
1.2.1 Lynparza
1.2.2 Zejula
1.2.3 Rubraca
1.2.4 Talzenna
1.2.5 Other
1.3 Market Analysis by Applications
1.3.1 Ovarian Cancer
1.3.2 Breast Cancer
1.3.3 Other
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2014-2024)
1.4.1.2 Canada Market States and Outlook (2014-2024)
1.4.1.3 Mexico Market States and Outlook (2014-2024)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2014-2024)
1.4.2.2 France Market States and Outlook (2014-2024)
1.4.2.3 UK Market States and Outlook (2014-2024)
1.4.2.4 Russia Market States and Outlook (2014-2024)
1.4.2.5 Italy Market States and Outlook (2014-2024)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2014-2024)
1.4.3.2 Japan Market States and Outlook (2014-2024)
1.4.3.3 Korea Market States and Outlook (2014-2024)
1.4.3.4 India Market States and Outlook (2014-2024)
1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2014-2024)
1.4.4.2 Egypt Market States and Outlook (2014-2024)
1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
1.4.4.4 South Africa Market States and Outlook (2014-2024)
1.4.4.5 Turkey Market States and Outlook (2014-2024)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 AstraZeneca
2.1.1 Business Overview
2.1.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 AstraZeneca PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.2 Tesaro
2.2.1 Business Overview
2.2.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Tesaro PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.3 Merck & Co
2.3.1 Business Overview
2.3.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Merck & Co PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.4 Clovis Oncology
2.4.1 Business Overview
2.4.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Clovis Oncology PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
2.5 Pfizer
2.5.1 Business Overview
2.5.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Pfizer PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
3 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)
3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Manufacturer (2017-2018)
3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Manufacturer (2017-2018)
3.3 Market Concentration Rate
3.3.1 Top 3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2018
3.3.2 Top 6 PARP (Poly ADP-Ribose Polymerase) Inhibitor Manufacturer Market Share in 2018
3.4 Market Competition Trend
4 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Analysis by Regions
4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Regions
4.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Regions (2014-2019)
4.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Regions (2014-2019)
4.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.3 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.4 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.5 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
4.6 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
5.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
5.1.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
5.1.2 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
5.2 United States PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5.3 Canada PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
5.4 Mexico PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
6.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
6.1.1 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
6.1.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
6.2 Germany PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.3 UK PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.4 France PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.5 Russia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
6.6 Italy PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
7.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
7.1.1 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
7.1.2 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
7.2 China PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.3 Japan PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.4 Korea PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.5 India PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
7.6 Southeast Asia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor by Country
8.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
8.1.1 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
8.1.2 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
8.2 Brazil PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8.3 Argentina PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
8.4 Colombia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor by Countries
9.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Country
9.1.1 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Country (2014-2019)
9.1.2 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Country (2014-2019)
9.2 Saudi Arabia PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.3 Turkey PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.4 Egypt PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.5 Nigeria PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
9.6 South Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Growth Rate (2014-2019)
10 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Type
10.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Market Share by Type (2014-2019)
10.1.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales and Market Share by Type (2014-2019)
10.1.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Revenue and Market Share by Type (2014-2019)
10.2 Lynparza Sales Growth and Price
10.2.1 Global Lynparza Sales Growth (2014-2019)
10.2.2 Global Lynparza Price (2014-2019)
10.3 Zejula Sales Growth and Price
10.3.1 Global Zejula Sales Growth (2014-2019)
10.3.2 Global Zejula Price (2014-2019)
10.4 Rubraca Sales Growth and Price
10.4.1 Global Rubraca Sales Growth (2014-2019)
10.4.2 Global Rubraca Price (2014-2019)
10.5 Talzenna Sales Growth and Price
10.5.1 Global Talzenna Sales Growth (2014-2019)
10.5.2 Global Talzenna Price (2014-2019)
10.6 Other Sales Growth and Price
10.6.1 Global Other Sales Growth (2014-2019)
10.6.2 Global Other Price (2014-2019)
11 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Segment by Application
11.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Market Share by Application (2014-2019)
11.2 Ovarian Cancer Sales Growth (2014-2019)
11.3 Breast Cancer Sales Growth (2014-2019)
11.4 Other Sales Growth (2014-2019)
12 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales, Revenue and Growth Rate (2019-2024)
12.2 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Regions (2019-2024)
12.2.1 North America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.2 Europe PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.3 Asia-Pacific PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.4 South America PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.2.5 Middle East and Africa PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast (2019-2024)
12.3 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Type (2019-2024)
12.3.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Type (2019-2024)
12.3.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Type (2019-2024)
12.4 PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Forecast by Application (2019-2024)
12.4.1 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Sales Forecast by Application (2019-2024)
12.4.2 Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market Share Forecast by Application (2019-2024)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure PARP (Poly ADP-Ribose Polymerase) Inhibitor Picture
Table Product Specifications of PARP (Poly ADP-Ribose Polymerase) Inhibitor
Figure Global Sales Market Share of P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
